Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: a new month and start of Q2

April 1, 2019 7:40am

The IBB (+0.77%), the XBI (+1.26%) and the NASDAQ (+0.91%) are looking positive …

Beyond the numbers, fundamentals and facts; what is the story that reinforces or” cons” perception?

… Cash positions, runways, trial read-outs as well as timing to an IND; remember a management team is an on-going catalyst that fuels or “screws” share value

My pre-open focus is indication analysis. An indication can be a development of almost any kind. Specifically, it may be a confirmed fact, a possible fact, or an absence of “something”, a fragment of information or even an observation!

It’s an honor to be considered the “canary in the (sectors) coal mine”! I devote my time to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!

Dow futures are UP +0.69% (+178 points), S&P futures are UP +0.63% (+18 points) and NASDAQ futures are UP +0.92% (+68 points)

U.S. stock futures rallied early on Monday following strong manufacturing data out of China.

European stocks jumped as investors in Europe digested stronger-than-expected Chinese data.

Asia markets surged following data released over the weekend that showed economic activity in China unexpectedly bouncing back in March.

Data docket: U.S. retail sales, manufacturing numbers, and construction spending and business inventories due to be released.

Monday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +0.77% UPSIDE;

The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +1.26% UPSIDE;

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating;

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.64% UPSIDE;

Henry’omics:

Traders are turning their focus to economic figures from China as a private survey showed the country’s manufacturing activity expanded unexpectedly in March, at its fastest pace in eight months. The figures gave some much-needed relief to investors unnerved of late by fears of a global economic downturn. Early last week, equities came under pressure as bond markets indicated an impending U.S. recession <CNBC>.

Past performance is no guarantee of future results but, do investors realize or even know that “warning intelligence deals with that which is obvious but, which is obscure”?

Despite Q4 and FY18 “earnings” season’s share pricing setbacks; the last three months have trended higher yet 9 of the past 10 times the S&P 500 was up at least 10% during Q1.

Markets found a base at 2,800 on the S&P 500, with last week’s pullback turned into last week’s sector gains. In an atmosphere where there’s not much news to trade upon, there has been little to justify the buying spree, it’s not really surprising that the oversold stimulated the swing of March’s ending.

Low volume bagged momentum keeping traders into equities but, will or can it continue?

From Friday’s closing bell post, “last trading session of March and Q1/18 ends; when you look at Q1, one thing that stands-out is the direction and divergence in the sector as the timing of “my” indication and quantamental analysis strikes a chord for portfolio appreciation.”

Range of the 32 upside was +0.12% (ONCE) to +13.26% (RENE.L) while the 11 downside ranged from -0.17% (BLFS) to -4.07% (SLDB);
5 out of the 32 upside had higher (than the 3 month average) volume;
3 out of the 11 downside experienced greater volume (than the 3 month average);
In March’s 21 sessions, there were 7 negative and 14 positive closes;

In the last five (5) sessions, the IBB has been up +3.36%

Companies in my headlights – It’s your decision; I provide an idea and context:

I would be watching how the session starts and navigate ANY upside to an advantage.

I’d be building CASH positions in the portfolio by SELLING into strength

… This market can NOT be trusted in regard to pricing sustainability!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.